GlassScriptPhysician profile
James Ketchum
NPI 1386610376
$4,497.87
in general payments reported to CMS, 2019-2025
35 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $397 · 2021: $52.55 · 2022: $603 · 2023: $864 · 2024: $968 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $809.85 | 2020-2025 | |
| Lilly USA, LLC | $660.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $506.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $334.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.33 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $253.78 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $218.06 | 2019-2025 | |
| Amgen INC. | $192.95 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $139.73 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $126.17 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $115.87 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.38 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.44 | 2025 | Caplyta |
| Optinose US, INC. | $57.58 | 2020-2022 | |
| Axsome Therapeutics, INC. | $55.59 | 2024-2025 | Symbravo, Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $53.74 | 2019-2020 | |
| Tris Pharma INC | $52.74 | 2024-2025 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $50.31 | 2022-2025 | |
| Amarin Pharma, INC. | $46.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.98 | 2023-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Sanofi-Aventis U.S. LLC | $45.22 | 2019 | |
| Esperion Therapeutics, INC. | $40.15 | 2020-2024 | Nexletol |
| Ironshore Pharmaceuticals INC. | $37.06 | 2019-2024 | |
| Allergan, INC. | $35.99 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.78 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $24.10 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.66 | 2022 | |
| Genentech USA, INC. | $18.71 | 2020 | |
| Nevro Corp. | $17.33 | 2023 | Senza |
| Eisai INC. | $15.57 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $14.07 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $13.90 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $13.67 | 2019 | |
| Kaleo, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ketchum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.